The NASH Summit offers an unrivalled, market leading opportunity to learn cutting-edge insights into the successes, setbacks and innovations in NASH drug development from the last 12 months. As the only totally comprehensive forum covering all aspects of NASH drug development from mechanistic science through to market access intelligence, this exclusively NASH dedicated conference is the meeting of the year in the NASH biopharma calendar.
Join over 80 speakers and 300 attendees across 4 days of unrivalled depth and breadth of discussion broken down into:
- 4 tracks hosting scientific case studies and thought leading panel analysis of discovery, translational and clinical drug development, and non-invasive biomarker application in the clinical algorithm of care
- 7 discussion driven, expert led workshops into: epigenetics, targeting the inflammasome, assessing translational models and non-invasive evaluations of NAFLD and NASH; understanding NASH associated-hepatocellular carcinoma, drug safety in NASH, and regulatory and clinical considerations for paediatric NASH
- 2 forward thinking seminars dedicated to applying relationships and lessons learned from wider anti-fibrotic drug development for pulmonary, renal and cardiac fibrosis to hepatic fibrosis, and understanding the market access challenges associated with NASH including the pricing and reimbursement considerations
Join conference chair Jason Campagna, Chief Medical Officer at Intercept, and 350+ attendees as the community comes together again to address challenges and the consequences of change in the next generation of the NASH market.
Time: 07:50 - 16:00
Gold - Conference + 2 Focus Days - Standard Price for Drug Developers: USD 4797.00,
Gold - Conference + 2 Focus Days - Early Admission Price for Drug Developers: USD 3797.00,
Gold - Conference + 2 Focus Days - Standard Price for Service Providers: USD 5397.00,
Gold - Conference + 2 Focus Days - Early Admission Price for Service Providers: USD 4397.00
Speakers: Ariel Feldstein - Professor and Chief, Pediatric Gastroenterology - UC San Diego, Bin Gao - Chief, Laboratory of Liver Diseases - NIAAA NIH, Frank Anania -Acting Clinical Team Leader, Division of Gastroenterology and Inborn Errors Products FDA, Johannes Taminiau - Pediatric Committee (PDCO), European Medicines Agency (EMA), Pediatric Gastroenterologist University Hospital Antwerp/Paola Children’s Hospital (Belgium), Vijay Shah -Consultant, Division of Gastroenterology and Hepatology, Department of Internal Medicine Mayo Clinic, Adrienne Stoudenmire- Director, Project Management, Cardiovascular/Metabolic Therapeutic Group ICON, Ajit Dash - Safety Science Associate Medical Director Genentech, Alka Shaunik - Senior Director – Global Medical Affairs Sanofi, Andrew Billin - Director, Biomarker Sciences Gilead, Ankang Li - Chief Finance Officer Terns Pharmaceuticals, Ann-Marie Richard - Patient and External Association Engagement Lead Pfizer, Becky Taub - Chief Medical Officer, Executive Vice President, Research and Development Madrigal Pharmaceuticals, Bill Esler - Senior Director Pfizer, Bob Zhang - Chief Executive Officer Kunming Biomed International (KBI), Bryan Fuchs - Therapeutic Area Head, GI and Liver Disease Ferring International, Chandra Saravanan - Senior Veterinary Pathologist Novartis Institutes for BioMedical Research (NIBR), Claudio Mori - Medical Strategy and Portfolio Lead Vifor Pharma, Daren Ure - Chief Scientific Officer Hepion Pharmaceuticals, David Woodhouse - Chief Executive Officer NGM Biopharmaceuticals, Deepa Rajagopalan - Executive Director, Strategic Planning, Enterprise Management, NASH and Primary Biliary Cholangitis Intercept, Deepak Kumar Rajpal - Head, Bioinformatics, Translational Sciences, US Sanofi, Derek Achila - Director and Senior Analyst – Biotechnology Stifel Nicolaus, Eduardo Martins - Vice President, Clinical Development Allergan, Elias Paptheodorou - Chief Executive Officer Genkyotex, Francois Briand-Director, Research and Business Development Physiogenex, Glenn Rosen - Vice President - Preclinical Translational Sciences and Small Molecules Coherus Biosciences, Hank Mansbach - Chief Medical Officer 89Bio, Harold Shlevin - Chief Executive Officer and President Galectin Therapeutics, Heather Hsu - Chief Scientific Officer Inipharm, Hubert Chen - Chief Medical Officer Metacrine, Jason Campagna - Senior Vice President and Global NASH Lead Intercept, Jay Chuang - Senior Scientist Gilead, Jeffrey Wager - Chairman and Chief Executive Officer Proterris, Jerry Colca - Chief Scientific Officer Cirius Therapeutics, Joanne Imperial - Vice President, Clinical Research Blade Therapeutics, Julia Brosnan - Senior Director, External Collaborations and Scientific Alliances Pfizer, Kyungil Kim Chief Operating Officer and Chief Scientific Officer Glaceum, Liat Hayardeny - Chief Scientific Officer Galmed Pharmaceuticals, Manu Chakravarty - Chief Medical Officer and Senior Vice President Axcella Health, Maria Wilson - Project Team Leader Genentech, Mark Feitelson - Chief Scientific Officer SFA Therapeutics, Martijn Fenaux - Vice President and Head of Biology Terns Pharmaceuticals, Melissa Palmer - Independent Consultant, (Formerly) Head of Liver Disease Development Takeda, Michael Badman - Translational Medicine Expert Novartis, Nikolai Naoumov - Executive Director, Hepatology Science and Innovation Novartis, Peter Traber - Partner Alacrita Consulting, RJ Tesi - Chief Executive Officer and Chief Medical Officer INmune Bio, Roberto Calle - Executive Director Pfizer, Rugmani Padmanabhan Iyer - Senior Scientist – Cardiovascular, Inflammation and Fibrosis Merck, Rusty Montgomery - Director, Research Miragen Therapeutics, Scott Harris - Chief Medical Officer Altimmune, Star Seyedkazemi - Associate Vice President, Clinical Development Allergan, Stephen Rossi - Vice President, Early Clinical Development CymaBay Therapeutics, Tom Wynn - Vice President, Discovery Inflammation and Immunology Pfizer, Weilin Xie - Senior Principal Scientist Celgene, Yasmeen Rahimi - MD and Senior Research Analyst, Co-Head of Biotechnology Research ROTH Capital Partners, Davide Povero - Senior Research Scientist, Department of Biochemistry and Molecular Biology Mayo Clinic, Hannah Drescher - Postdoctoral Research Fellow Massachusetts General Hospital, Jagpreet Chhatwal - Assistant Professor Harvard Medical School, Jelena Mann - Professor of Epigenetics Newcastle University, Kathleen Corey - Director, MGH Fatty Liver Clinic, MGH Gastrointestinal Unit Massachusetts General Hospital, Laura Nagy - Professor Molecular Medicine, Staff in Pathobiology and Gastroenterology, Lerner Research Institute Cleveland Clinic, Lee Borthwick - Fibrosis Biology Lecturer Newcastle University, Naim Alkhouri - Director of the Metabolic Center The Texas Liver Institute, Neil Henderson - Chair of Tissue Repair and Regeneration, Centre for Inflammation Research University of Edinburgh, Peter Caravan - Co-Director Institute for Innovation in Imaging Massachusetts General Hospital, Yury Popov - Assistant Professor of Medicine Beth Israel Deaconess Medical Center, Anthony and Betsy Villioti - President and Co- Founders NASH Knowledge, Donna Cryer - President and Chief Executive Officer Global Liver Institute, Wayne Eskridge - Chief Executive Officer Fatty Liver Foundation